NCT07259252Recruiting
Influenza Vaccination After Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are: * Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke? * Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, stent thrombosis? If there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease. Participants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 6620 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- 3 Dec 2025
- Primary completion date
- 30 Mar 2029
- Lead sponsor
- Tongji Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07259252
What you commit to
- Study type: Interventional
- Planned participants: 6620
- From 3 Dec 2025 to the primary completion date, 30 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participate in any drug clinical trials within 3 months.
- Patients Received influenza vaccination within 1 year.
Other illness
- Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients).
- Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix).
Other
- Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years.
- Patients refused to comply with the requirements of this study to complete the research work.
- Patients with contraindications for influenza vaccination.
Who the study is looking for
- ACS patient aged from 18 to 80 years.
- Volunteer for the study and written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.